Marco Basiricò - Concepedia

Author

Marco Basiricò

Candiolo Cancer Institute ORCID

Also Known As

Cattaneo G, Landoni, Elisa, M. Basiricò, Marco Basiricò, Marco Basirico’, Marco Basiricò, Marco Basiricó

Publications

513

Citations

H-Index

Concepts

All Affiliations

Candiolo Cancer Institute University of Turin Istituti di Ricovero e Cura a Carattere Scientifico Fondazione Edo ed Elvo Tempia Istituto Ortopedico Rizzoli

About

Marco Basiricò is an author at Candiolo Cancer Institute specializing in tumor biology, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	53
2	Cell Biology	2	2	53
3	Pathology	2	2	53
4	Immunology	1	1	22
5	Pharmacology	1	1	31

Marco Basiricò

Publications

454

Citations

H-Index

Page 1

	Year	Citations
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models Ymera Pignochino, Carmine Dell’Aglio, Marco Basiricò, Clinical Cancer Research	2013	107
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Molecular Cancer	2017	69
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody Martina Sanlorenzo, Igor Vujic, Arianna Floris, Clinical Cancer Research	2018	53
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes Valeria Leuci, Chiara Donini, Giovanni Grignani, Clinical Cancer Research	2020	38
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma Ymera Pignochino, Carmine Dell’Aglio, Simona Inghilleri, BMC Cancer	2015	34
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. Giulia Mesiano, Giovanni Grignani, Erika Fiorino, OncoImmunology	2018	33
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights Giulia Chiabotto, Giovanni Grignani, Maja Todorovic, Cancers Advanced OsteosarcomaPathologyCell DeathTumor BiologyRtk Pathways	2020	31
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine Chiara Varamo, Caterina Peraldo‐Neia, Paola Ostano, Cancers	2019	28
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST Erika Fiorino, Alessandra Merlini, Lorenzo D’Ambrosio, International Journal of Molecular Sciences ImmunologyImmune RegulationPathologyImmunoeditingBiological Therapy	2022	22
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient Caterina Peraldo‐Neia, Annamaria Massa, Francesca Vita, Cancers	2021	16

Page 1